One Unifying Technology from Concept to Clinic.

MaxCyte
in one minute.

Play Video

We are a U.S.-based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines. We understand and scientifically solve partners’ challenges by applying our expertise.

Find Out How

Life Science
for the ExPERT.

Through its Life Sciences business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. We call this line of products our ExPERT platform.

Explore the ExPERT Platform

Any Cell. Any Molecule. Any Scale.

The ExPERT Family of Flow Electroporation® Instruments

Cell Therapies
with CARMA.

CARMA® is MaxCyte's patented mRNA-based platform for cell therapy development, allowing for the possibility of one-day manufacturing.

Explore the CARMA Program

Cell and gene
therapies

Functional
cell-based assay

Gene editing

Protein and antibody
expression

Stable cell line
development

Viral vector
production

Previously unfeasible
cell-engineering
applications.

Our cell-engineering platform harnesses the power of the cell to accelerate the development of small molecule drugs, biologics, vaccines and cell and gene therapies to address a wide array of acute and chronic disease indications.

Explore applications

MaxCyte Inc. Rings the Nasdaq Stock Market Closing Bell

MaxCyte, Inc. (Nasdaq: MXCT),visits the Nasdaq MarketSite in Times Square. Doug Doerfler, President, Chief Executive Officer and Founder, rings the Closing Bell.

Event Details